Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

10. juli 2018 opdateret af: UCB Pharma

Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.

The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

439

Fase

  • Fase 3

Udvidet adgang

Ledig uden for det kliniske forsøg. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Adelaide, Australien
      • Bankstown, Australien
      • Clayton, Australien
      • Fitzroy, Australien
      • Fremantle, Australien
      • Garran, Australien
    • New South Wales
      • Concord, New South Wales, Australien
    • Victoria
      • Box Hill, Victoria, Australien
      • Footscray, Victoria, Australien
      • Parkville, Victoria, Australien
      • Bonheiden, Belgien
      • Brussels, Belgien
      • Gent, Belgien
      • Leuven, Belgien
      • Liege, Belgien
      • Roeselare, Belgien
      • Curitiba, Brasilien
      • Goiania, Brasilien
      • Porto Alegre, Brasilien
      • Rio de Janeiro, Brasilien
      • Santo-Andre, Brasilien
      • Santos, Brasilien
      • Sao Paulo, Brasilien
    • MG
      • Belo-Horizonte, MG, Brasilien
      • Calgary, Canada
    • Alberta
      • Edmonton, Alberta, Canada
    • British Columbia
      • Kelowna, British Columbia, Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada
    • Ontario
      • Hamilton, Ontario, Canada
      • Kingston, Ontario, Canada
      • London, Ontario, Canada
      • Toronto, Ontario, Canada
      • Santiago, Chile
      • Vina del Mar, Chile
      • Kazan, Den Russiske Føderation
      • Moscow, Den Russiske Føderation
      • St. Petersburg, Den Russiske Føderation
      • Tallin, Estland
      • Tartu, Estland
      • Mikkeli, Finland
    • Alabama
      • Pell City, Alabama, Forenede Stater
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater
      • Lakewood, Colorado, Forenede Stater
      • Littleton, Colorado, Forenede Stater
    • Florida
      • Hollywood, Florida, Forenede Stater
      • Jacksonville, Florida, Forenede Stater
      • New Port Richey, Florida, Forenede Stater
      • Winter Park, Florida, Forenede Stater
    • Illinois
      • Chicago, Illinois, Forenede Stater
    • Kentucky
      • Louisville, Kentucky, Forenede Stater
    • Louisiana
      • Metairie, Louisiana, Forenede Stater
      • Monroe, Louisiana, Forenede Stater
    • Maryland
      • Annapolis, Maryland, Forenede Stater
      • Towson, Maryland, Forenede Stater
    • Michigan
      • Chesterfield, Michigan, Forenede Stater
      • West Bloomfield, Michigan, Forenede Stater
    • Minnesota
      • Rochester, Minnesota, Forenede Stater
    • North Carolina
      • Raleigh, North Carolina, Forenede Stater
    • Ohio
      • Cincinnati, Ohio, Forenede Stater
      • Cleveland, Ohio, Forenede Stater
    • Pennsylvania
      • Lancaster, Pennsylvania, Forenede Stater
    • Tennessee
      • Germantown, Tennessee, Forenede Stater
    • Virginia
      • Norfolk, Virginia, Forenede Stater
    • Washington
      • Seattle, Washington, Forenede Stater
      • Beer Sheva, Israel
      • Haifa, Israel
      • Holon, Israel
      • Jerusalem, Israel
      • Kfar Saba, Israel
      • Petha Tikva, Israel
      • Rehovot, Israel
      • Tel Aviv, Israel
      • Zerifin, Israel
      • Bologna, Italien
      • Padova, Italien
      • Roma, Italien
      • Riga, Letland
      • Valmiera, Letland
      • Auckland, New Zealand
      • Christchurch, New Zealand
      • Hamilton, New Zealand
    • Auckland
      • Milford, Auckland, New Zealand
    • Wellington
      • Newton, Wellington, New Zealand
      • Czestochowa, Polen
      • Lodz, Polen
      • Warszawa, Polen
      • Wroclaw, Polen
      • Bucharest, Rumænien
      • Cluj Napoca, Rumænien
      • Constanta, Rumænien
      • Hradec Kralove, Tjekkiet
      • Hradek Kralove, Tjekkiet
      • Praha 7, Tjekkiet
      • Usti Nad Orlici, Tjekkiet
      • Zlin, Tjekkiet
      • Berlin, Tyskland
      • Frankfurt, Tyskland
      • Freiburg, Tyskland
      • Homburg, Tyskland
      • Jena, Tyskland
      • Kiel, Tyskland
      • Munchen, Tyskland
      • Ulm, Tyskland
      • Wilhelmshaven, Tyskland
      • Dniepropetrovsk, Ukraine
      • Donetsk, Ukraine
      • Kiev, Ukraine
      • Kyiv, Ukraine
      • Lviv, Ukraine
      • Simferopol, Ukraine
      • Budapest, Ungarn
      • Gyor, Ungarn
      • Nagykanizsa, Ungarn
      • Szeged, Ungarn
      • Szombathely, Ungarn
      • Wien, Østrig

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • male/female
  • 18 - 75 years inclusive
  • diagnosis of Crohn's disease confirmed
  • moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
  • no previous treatment with anti-tumor necrosis factor (anti-TNF) medications

Exclusion Criteria:

  • previous participation in a certolizumab pegol study
  • general exclusion criteria as common for studies in this indication

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Andre navne:
  • CZP
  • CDP870
  • CIMZIA ®
Placebo komparator: Placebo
Placebo, saline solution for sc injection
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Subjects in Clinical Remission at Week 6
Tidsramme: Week 6
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 6

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Subjects Achieving a Clinical Response at Week 6
Tidsramme: Week 0, Week 6
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0, Week 6
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
Tidsramme: Week 6
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more). The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
Week 6
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
Tidsramme: Week 0 to Week 6
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0 to Week 6
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
Tidsramme: Week 0 to Week 6
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item). The first three items are scored for the previous day. Lower scores indicated better well being.
Week 0 to Week 6
Percentage of Subjects in Clinical Remission at Week 2
Tidsramme: Week 2
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 2
Percentage of Subjects in Clinical Remission at Week 4
Tidsramme: Week 4
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 4
Percentage of Subjects Achieving a Clinical Response at Week 2
Tidsramme: Week 0, Week 2
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0, Week 2
Percentage of Subjects Achieving a Clinical Response at Week 4
Tidsramme: Week 0, Week 4
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0, Week 4
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
Tidsramme: Week 0 to Week 2
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0 to Week 2
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
Tidsramme: Week 0, Week 4
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0, Week 4
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
Tidsramme: Week 2
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more). The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
Week 2
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
Tidsramme: Week 4
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more). The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
Week 4
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Tidsramme: Week 6
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 6
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Tidsramme: Week 6
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 6
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Tidsramme: Week 0, Week 6
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0, Week 6
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Tidsramme: Week 0, Week 6
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score). CDAI is used to quantify the symptoms of subjects with Crohn's disease. A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
Week 0, Week 6

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2008

Primær færdiggørelse (Faktiske)

1. oktober 2009

Studieafslutning (Faktiske)

1. november 2009

Datoer for studieregistrering

Først indsendt

18. oktober 2007

Først indsendt, der opfyldte QC-kriterier

31. oktober 2007

Først opslået (Skøn)

1. november 2007

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. august 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. juli 2018

Sidst verificeret

1. oktober 2011

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner